Literature DB >> 28429199

Gastric Bypass and Influence on Improvement of NAFLD.

Vamsi Alli1, Ann M Rogers2.   

Abstract

PURPOSE OF REVIEW: Obesity is recognized as a chronic and recurring disease, often accompanied by other weight-related comorbid conditions such as obstructive sleep apnea, hypertension, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). This chapter will seek to focus on the effect of weight loss surgery (WLS), in particular Roux-en-Y gastric bypass (RYGB), on NAFLD. RECENT
FINDINGS: Among several modalities available to treat NAFLD, the one most likely to achieve rapid, significant, and sustained improvement of liver disease is WLS. The most commonly studied WLS procedure at this time is RYGB, and there is significant evidence that this is a safe and effective procedure both for weight loss and to bring about improvement of multiple associated comorbid conditions, including NAFLD. Further research focusing on non-surgical approaches that might mimic the effect of WLS on liver pathology is needed.

Entities:  

Keywords:  Bariatric surgery; Fatty liver; Gastric bypass; Liver disease; Liver steatosis; Weight loss; Weight loss surgery

Mesh:

Year:  2017        PMID: 28429199     DOI: 10.1007/s11894-017-0567-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  31 in total

Review 1.  Impact of bariatric surgery on comorbidities.

Authors:  Ashutosh Kaul; Jyoti Sharma
Journal:  Surg Clin North Am       Date:  2011-10-02       Impact factor: 2.741

2.  Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome.

Authors:  K Qureshi; G A Abrams
Journal:  Clin Obes       Date:  2016-02-08

3.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

4.  Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study.

Authors:  Everton Cazzo; Laísa Simakawa Jimenez; José Carlos Pareja; Elinton Adami Chaim
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

Review 5.  Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation.

Authors:  S M Strasberg; T K Howard; E P Molmenti; M Hertl
Journal:  Hepatology       Date:  1994-10       Impact factor: 17.425

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

Review 7.  Bariatric surgery and the gut hormone response.

Authors:  Susan Thomas; Philip Schauer
Journal:  Nutr Clin Pract       Date:  2010-04       Impact factor: 3.080

Review 8.  Nonalcoholic Fatty Liver Disease and Liver Transplantation.

Authors:  Tuan Pham; Travis B Dick; Michael R Charlton
Journal:  Clin Liver Dis       Date:  2016-05       Impact factor: 6.126

9.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

10.  Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis.

Authors:  Anne-Sophie Schneck; Rodolphe Anty; Stéphanie Patouraux; Stéphanie Bonnafous; Déborah Rousseau; Cynthia Lebeaupin; Beatrice Bailly-Maitre; Arnaud Sans; Albert Tran; Jean Gugenheim; Antonio Iannelli; Philippe Gual
Journal:  Front Physiol       Date:  2016-08-19       Impact factor: 4.566

View more
  4 in total

1.  A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.

Authors:  Mao-Xu Ge; Wei-Xiao Niu; Jin-Feng Ren; Shi-Ying Cai; Dong-Ke Yu; Hong-Tao Liu; Na Zhang; Yi-Xuan Zhang; Yu-Cheng Wang; Rong-Guang Shao; Ju-Xian Wang; Hong-Wei He
Journal:  Acta Pharmacol Sin       Date:  2018-12-20       Impact factor: 6.150

Review 2.  Current Controversies in Metabolic Surgery for Nonalcoholic Fatty Liver Disease.

Authors:  Iraklis Perysinakis; Harilaos C Pappis; Elias Margaris
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

3.  Body weight-dependent and independent improvement in lipid metabolism after Roux-en-Y gastric bypass in ApoE*3Leiden.CETP mice.

Authors:  Erika Tarasco; Christina N Boyle; Giovanni Pellegrini; Myrtha Arnold; Regula Steiner; Thorsten Hornemann; Dimitris Nasias; Dimitris Kardassis; Lynda Whiting; Thomas A Lutz
Journal:  Int J Obes (Lond)       Date:  2019-07-03       Impact factor: 5.095

4.  ACCURACY OF ELASTOGRAPHY IN THE ASSESSMENT OF REDUCTION IN LIVER STEATOSIS AND FIBROSIS IN THE EARLY POSTOPERATIVE PERIOD AFTER BARIATRIC SURGERY.

Authors:  Ramon Rawache Lima; José Huygens Parente Garcia; Marina Seixas Studart; Fernando Siqueira Pinheiro; João Odilo Gonçalves Pinto; Leonardo Adolpho Sales; Lucas Marrocos Soares; Priscilla de Almeida Santos
Journal:  Arq Bras Cir Dig       Date:  2022-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.